DFJ led the investment round with China-based WuXi AppTech’s corporate venture fund, the ALS Investment Fund, Agent Capital and the OS Fund. Verge Genomics was formed in 2015 and investment now totals $68 million. The venture focuses on neuroscience and experimental biology and has created proprietary patient genomic datasets for neurodegenerative diseases including Parkinson’s disease and ALS.
Co-Founder and CEO Alice Zhang reports that “by vertically integrating machine learning and drug development capabilities under one roof, we have been able to quickly identify dozens of promising new therapeutic opportunities for devastating diseases such as ALS and Parkinson’s disease.” Zhang has been able to attract a balance investor syndicate representing “the biotech and technology sectors.”
View article hereSource: Genomeweb